Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

Sponsor
GlaxoSmithKline
Study ID
NCT00350727
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • pazopanib — DRUG
    Pazopanib is a novel compound being developed for the treatment of various cancers.
  • lapatinib — DRUG
    Lapatinib is a novel compound being developed for the treatment of various cancers.

Study Details

This study is being conducted to characterize the safety/tolerability of pazopanib and lapatinib when administered in combination with enzyme-inducing anticonvulsants in patients with recurrent Grade III or IV malignant gliomas.

Key Dates

Start date
Dec 31, 2006
Status verified
May 2012
Primary completion
Dec 31, 2009
Completion
Dec 31, 2009

Study Design

Enrollment
75 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Combination
    Pazopanib and Lapatinib in combination. Subjects remain on treatment until disease progression or withdrawal from study.

Primary Outcome Measure

Number of Participants With the Indicated Change From Baseline to Study Completion in Systolic Blood Pressure [ Time Frame: Baseline to study completion (up to 844 days for Phase I, up to 878 days for Phase II) ]

Related Studies